AAUM (Average Assets Under Management) of ₹263.63 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 70.5% | 74.8% | ▲ +4.3% |
| Healthcare Services | 21.1% | 20.9% | ▼ -0.2% |
| Healthcare Equipment & Supplies | 1.5% | 1.5% | ● 0.0% |
| Industrial Products | 1.9% | 1.2% | ▼ -0.7% |
| Chemicals & Petrochemicals | 1.1% | 0.9% | ▼ -0.2% |
| Aerospace & Defense | 0.5% | 0.0% | ▼ -0.5% |
| Banks | 0.5% | 0.0% | ▼ -0.5% |
| Retailing | 0.9% | 0.0% | ▼ -0.9% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 74.8% | 75.1% | ▲ +0.3% |
| Healthcare Services | 20.9% | 20.4% | ▼ -0.5% |
| Healthcare Equipment & Supplies | 1.5% | 1.3% | ▼ -0.2% |
| Industrial Products | 1.2% | 1.3% | ● +0.0% |
| Chemicals & Petrochemicals | 0.9% | 0.8% | ▼ -0.1% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Laurus Labs Limited ₹12.10 Cr |
Pharmaceuticals & Biotechnology | 4.02% | 4.54% | +0.52% |
| 2 | Divi's Laboratories Limited ₹26.63 Cr |
Pharmaceuticals & Biotechnology | 9.51% | 9.98% | +0.47% |
| 3 | Gland Pharma Limited ₹4.01 Cr |
Pharmaceuticals & Biotechnology | 1.03% | 1.50% | +0.47% |
| 4 | Dr. Reddy's Laboratories Limited ₹13.95 Cr |
Pharmaceuticals & Biotechnology | 4.78% | 5.23% | +0.45% |
| 5 | Metropolis Healthcare Limited ₹2.43 Cr |
Healthcare Services | 0.71% | 0.91% | +0.20% |
| 6 | Fortis Healthcare Limited ₹7.89 Cr |
Healthcare Services | 2.77% | 2.96% | +0.19% |
| 7 | Apollo Hospitals Enterprise Limited ₹14.99 Cr |
Healthcare Services | 5.45% | 5.62% | +0.17% |
| 8 | Cipla Limited ₹11.41 Cr |
Pharmaceuticals & Biotechnology | 4.19% | 4.28% | +0.09% |
| 9 | Aster DM Healthcare Limited ₹4.41 Cr |
Healthcare Services | 1.59% | 1.65% | +0.06% |
| 10 | Zydus Lifesciences Limited ₹2.09 Cr |
Pharmaceuticals & Biotechnology | 0.73% | 0.78% | +0.05% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Healthcare Global Enterprises Limited ₹2.38 Cr |
Healthcare Services | 1.47% | 0.89% | -0.58% |
| 2 | Max Healthcare Institute Limited ₹11.04 Cr |
Healthcare Services | 4.49% | 4.14% | -0.35% |
| 3 | Neuland Laboratories Limited ₹7.29 Cr |
Pharmaceuticals & Biotechnology | 3.07% | 2.73% | -0.34% |
| 4 | Shilpa Medicare Ltd ₹3.43 Cr |
Pharmaceuticals & Biotechnology | 1.61% | 1.29% | -0.32% |
| 5 | Sun Pharmaceutical Industries Limited ₹31.14 Cr |
Pharmaceuticals & Biotechnology | 11.96% | 11.67% | -0.29% |
| 6 | Torrent Pharmaceuticals Limited ₹12.21 Cr |
Pharmaceuticals & Biotechnology | 4.78% | 4.58% | -0.20% |
| 7 | Global Health Limited ₹7.07 Cr |
Healthcare Services | 2.85% | 2.65% | -0.20% |
| 8 | Poly Medicure Limited ₹3.41 Cr |
Healthcare Equipment & Supplies | 1.48% | 1.28% | -0.20% |
| 9 | Abbott India Limited ₹5.39 Cr |
Pharmaceuticals & Biotechnology | 2.14% | 2.02% | -0.12% |
| 10 | SUPRIYA LIFESCIENCE LIMITED ₹2.37 Cr |
Pharmaceuticals & Biotechnology | 1.00% | 0.89% | -0.11% |
37 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹31.14 Cr |
Pharmaceuticals & Biotechnology |
11.67%
|
|
| 2 |
₹26.63 Cr |
Pharmaceuticals & Biotechnology |
9.98%
|
|
| 3 |
₹14.99 Cr |
Healthcare Services |
5.62%
|
|
| 4 |
₹13.95 Cr |
Pharmaceuticals & Biotechnology |
5.23%
|
|
| 5 |
₹12.21 Cr |
Pharmaceuticals & Biotechnology |
4.58%
|
|
| 6 |
₹12.10 Cr |
Pharmaceuticals & Biotechnology |
4.54%
|
|
| 7 |
₹11.41 Cr |
Pharmaceuticals & Biotechnology |
4.28%
|
|
| 8 |
₹11.04 Cr |
Healthcare Services |
4.14%
|
|
| 9 |
₹10.74 Cr |
Pharmaceuticals & Biotechnology |
4.03%
|
|
| 10 |
₹10.01 Cr |
Pharmaceuticals & Biotechnology |
3.75%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.